Intercept Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6/19/2013 10:12:35 AM
More...
|
Intercept Pharmaceuticals Announces Proposed Public Offering of Common Stock
6/17/2013 9:04:06 AM
More...
|
Intercept Pharmaceuticals to Present at Deutsche Bank (DB) Healthcare Conference
5/23/2013 8:13:11 AM
More...
|
Intercept Pharmaceuticals Announces Additional Results of Global Primary Biliary Cirrhosis Study Group Analysis Presented at EASL
4/30/2013 11:42:25 AM
More...
|
Intercept Pharmaceuticals to Host 2012 Fourth Quarter and Full Year Financial Results Conference Call on March 18
3/12/2013 11:31:38 AM
More...
|
Intercept Pharmaceuticals Appoints Daniel Regan as Chief Commercial Officer
3/4/2013 11:25:05 AM
More...
|
Intercept Pharmaceuticals Announces Initiation of Phase 2 NASH Trial of OCA in Japan
1/8/2013 9:10:03 AM
More...
|
Intercept Pharmaceuticals Announces Completion of Enrollment in Phase 3 Primary Biliary Cirrhosis POISE Trial
12/19/2012 9:13:20 AM
More...
|
Intercept Pharmaceuticals Announces Completion of Enrollment in FLINT
11/12/2012 7:47:03 AM
More...
|
Intercept Pharmaceuticals to Present Phase 2a Portal Hypertension Data at American Association for Study of Liver Diseases's Liver Meeting
11/9/2012 10:15:55 AM
More...
|
|